Regulation of vascular endothelial growth factor expression by estrogens and progestins.
Estrogens increase the expression of vascular endothelial growth factor (VEGF) mRNA in the rodent uterus. This regulatory effect is rapid, beginning within 1 hr after hormone treatment, dose dependent, and blocked by the pure antiestrogen ICI 182,780. The induction of the transcript is blocked by inhibitors of RNA but not of protein synthesis, and we have recently identified estrogen response elements in the VEGF gene. Collectively, these findings indicate that estrogens regulate uterine VEGF expression at the transcriptional level via the classical nuclear estrogen receptor pathway. Estrogen induction of VEGF occurs in the stromal layer of the rodent uterus, and estradiol induces expression of VEGF transcript levels in cultured human uterine stromal cells. Progestins also induce VEGF expression in the rodent uterus, although the effect is less marked and slower in onset than estrogenic effects. The effect of progestins is blocked by the antiprogestin mifepristone (RU-486), suggesting that it is also mediated by a classical nuclear receptor pathway. In addition, progestins regulate expression of VEGF mRNA and protein in cultured human T47-D breast cancer cells. The development of uterine leiomyomas is associated with exposure to ovarian sex steroids, abnormal uterine bleeding is commonly seen in patients with leiomyomas, and fibroids require an increased vascular supply for their growth. These observations suggest that VEGF and other angiogenic factors may represent potential targets for the treatment and prevention of uterine fibroids.
Hyder
S M
SM
Department of Integrative Biology and Pharmacology, University of Texas-Houston Medical School, Houston, Texas 77225, USA. salman.hyder@uth.tmc.edu
Huang
J C
JC
Nawaz
Z
Z
Boettger-Tong
H
H
Mäkelä
S
S
Chiappetta
C
C
Stancel
G M
GM
D001943:Breast Neoplasms / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D016228:Endothelial Growth Factors / Q000145:classification / Q000235:genetics*; D004958:Estradiol / Q000031:analogs & derivatives / Q000494:pharmacology; D004965:Estrogen Antagonists / Q000494:pharmacology; D004967:Estrogens / Q000502:physiology*; D005260:Female; D000077267:Fulvestrant; D005786:Gene Expression Regulation / Q000502:physiology*; D006727:Hormone Antagonists / Q000494:pharmacology; D006801:Humans; D007889:Leiomyoma / Q000235:genetics / Q000628:therapy; D008222:Lymphokines / Q000145:classification / Q000235:genetics*; D015735:Mifepristone / Q000494:pharmacology; D011372:Progestins / Q000037:antagonists & inhibitors / Q000502:physiology*; D012333:RNA, Messenger / Q000235:genetics*; D011960:Receptors, Estrogen / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D015398:Signal Transduction / Q000502:physiology; D014158:Transcription, Genetic / Q000235:genetics; D014594:Uterine Neoplasms / Q000235:genetics / Q000628:therapy; D014599:Uterus / Q000502:physiology*; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D004965:Estrogen Antagonists; D004967:Estrogens; D006727:Hormone Antagonists; D008222:Lymphokines; D011372:Progestins; D012333:RNA, Messenger; D011960:Receptors, Estrogen; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D000077267:Fulvestrant; D015735:Mifepristone; D004958:Estradiol